Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?
Carlo MümmlerBernd KemmerichJürgen BehrNikolaus KneidingerKatrin MilgerPublished in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2020)
Our case highlights that a patient may exhibit differential treatment responses to the currently available asthma biologics and suggests switching treatment if outcome is insufficient. A potential role for dupilumab in the treatment of ABPA warrants future studies.
Keyphrases